

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

SV2A antibody

RRID:AB_778192

Type: Antibody

Proper Citation

Abcam Cat# ab32942, RRID:AB_778192

Antibody Information

URL: http://antibodyregistry.org/AB_778192

Proper Citation: Abcam Cat# ab32942, RRID:AB_778192

Target Antigen: SV2A

Host Organism: rabbit

Clonality: polyclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry; Western Blot; Immunocytochemistry/Immunofluorescence, Immunohistochemistry-FoFr, Immunohistochemistry-P, Western Blot

Antibody Name: SV2A antibody

Description: This polyclonal targets SV2A

Target Organism: rat, mouse, human

Antibody ID: AB_778192

Vendor: Abcam

Catalog Number: ab32942

Record Creation Time: 20250819T230834+0000

Record Last Update: 20250820T042508+0000

Ratings and Alerts

No rating or validation information has been found for SV2A antibody.

No alerts have been found for SV2A antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Espinosa-Garcia C, et al. (2026) Neuroinflammatory stress preferentially impacts synaptic MAPK signaling and mitochondria in excitatory neurons. *Molecular neurodegeneration advances*, 2(1), 17.

Sebastian RM, et al. (2026) SynCAR platform for capturing neuronal synaptic proteopathic seeds. *iScience*, 29(7), 116362.

Bonnycastle K, et al. (2025) Convergent depression of activity-dependent bulk endocytosis in rodent models of autism spectrum disorder. *Molecular autism*, 16(1), 26.

Tan HCG, et al. (2025) Increased Activity-Dependent Bulk Endocytosis in Huntington's Disease Results From Huntingtin Haploinsufficiency. *Journal of neurochemistry*, 169(6), e70134.

Lee Q, et al. (2025) Deficiency in N-cadherin-Akt3 signaling impairs the blood-brain barrier. *Cell reports*, 44(6), 115831.

Small C, et al. (2024) SV2A controls the surface nanoclustering and endocytic recruitment of Syt1 during synaptic vesicle recycling. *Journal of neurochemistry*, 168(9), 3188.

Kim N, et al. (2024) Delayed recruitment of activity-dependent bulk endocytosis in Fmr1 knockout neurons. *Journal of neurochemistry*, 168(9), 3019.

Blumrich EM, et al. (2023) Phosphatidylinositol 4-kinase II β is a glycogen synthase kinase 3-regulated interaction hub for activity-dependent bulk endocytosis. *Cell reports*, 42(6), 112633.

Lin NH, et al. (2023) Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. *Journal of Alzheimer's disease reports*, 7(1), 51.

Parra-Rivas LA, et al. (2023) Serine-129 phosphorylation of α -synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function. *Neuron*, 111(24), 4006.

López-Hernández T, et al. (2022) Clathrin-independent endocytic retrieval of SV proteins mediated by the clathrin adaptor AP-2 at mammalian central synapses. *eLife*, 11.

Dhandapani R, et al. (2022) Sustained Trem2 stabilization accelerates microglia heterogeneity and A β pathology in a mouse model of Alzheimer's disease. *Cell reports*, 39(9), 110883.

Bonnycastle K, et al. (2022) FMRP Sustains Presynaptic Function via Control of Activity-Dependent Bulk Endocytosis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 42(8), 1618.

Ivanova D, et al. (2021) Control of synaptic vesicle release probability via VAMP4 targeting to endolysosomes. *Science advances*, 7(18).

Sulsenti R, et al. (2021) Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. *Frontiers in immunology*, 12, 622001.

Jensen BK, et al. (2020) Synaptic dysfunction induced by glycine-alanine dipeptides in C9orf72-ALS/FTD is rescued by SV2 replenishment. *EMBO molecular medicine*, 12(5), e10722.

Salazar SV, et al. (2019) Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid- β -Induced Synaptic Dysfunction and Loss. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 39(4), 758.

Gunther EC, et al. (2019) Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists. *Cell reports*, 26(1), 145.

Chaney A, et al. (2018) Longitudinal investigation of neuroinflammation and metabolite profiles in the APP^{swe} $\times$ PS1^{e9} transgenic mouse model of Alzheimer's disease. *Journal of neurochemistry*, 144(3), 318.